Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Detection of Light-Chain Amyloidosis in Monoclonal Gammopathy Using 18F-Florbetaben PET/MR
NCT07624760Not yet recruiting
- Sponsor
- University of Zurich
- Start
- Oct 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Open-label trial of flutemetamol in amyloid light chain amyloidosis and Monoclonal gammopathy (MG) (3 arms), sponsored by University of Zurich. Primary endpoint: Systemic ¹⁸F-florbetaben PET positivity rate at Day 1. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
flutemetamol
03
Conditions
amyloid light chain amyloidosisMonoclonal gammopathy (MG)
Beyond the preview
Go deeper on NCT07624760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07624760.